References
- Nair S, Wilding JPH. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endo and Metab. 2010;34(1):34–42.
- Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539–545.
- Invokana Package Insert; Raritan NJ. Janssen Pharmaceuticals; 2016.
- Jardiance Package Insert; Ridgefield CT. Boehringer/Ingelheim Pharmaceuticals; 2016.
- Farxiga Package Insert; Wilmington DE. AstraZeneca Pharmaceuticals; 2016.
- Atkinson MA, Von herrath M, Powers C, et al. Current concepts on the pathogenesis of type 1 diabetes – considerations for attempts to prevent and reverse the Disease. Diabetes Care. 2015;38(6):979–988.
- Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 Inhibition. Diabetes Care. 2015;38:1687–1693.
- Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680–1686.
- Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–2265.
- Perkins BA, Cherney DZI, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480–1483.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334. DOI:10.1056/NEJMoa1515920.